InvestorsHub Logo

GS1

Followers 115
Posts 4767
Boards Moderated 0
Alias Born 07/11/2010

GS1

Re: None

Sunday, 01/11/2015 5:21:41 AM

Sunday, January 11, 2015 5:21:41 AM

Post# of 130503
Novartis decided to discontinue clinical trials of mavoglurant for the treatment of LID, due to the lack of efficacy demonstrated in trials NCT01385592 and NCT01491529, although no safety concerns were involved in this decision.

http://www.ncbi.nlm.nih.gov/pubmed/24960254

Also discontinued mavoglurant Fragile-X

http://www.fraxa.org/novartis-discontinues-development-mavoglurant-afq056-fragile-x-syndrome/


This means no competition for Eltoprazine.

Interesting to hear what Charlotte Keywood has to say about Eltoprizine in upcoming conference.

AMBS